AzTrials
AzTrials

Postspinal ShiveringNCT06762860

Intravenous Granisetron Vs Dexmedetomidine on Postspinal in the Cesarean Section.

A study testing Dexmedetomidine and Granisetron in people with Postspinal Shivering, run by Minia University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The Aim of this study is to investigate and compare the efficacy of intravenous Dexmedetomidine (0.3 ug/kg) versus intravenous Granisetron (3 mg) in the prevention of shivering in parturient undergoing cesarean section under spinal anesthesia. Read more about this study

Who is it for?
Ages 20 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Postspinal Shivering
What is being tested?
Dexmedetomidine and Granisetron
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
99 participants
Where
1 siteEgypt
Study dates
1 Jan 2024to 28 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • patients scheduled for cesarean section under spinal anesthesia.
  • age : (20-45) years old.
  • American Society of Anesthesia (ASA) physical status I, II.

Who cannot join

  • Patient refusal.
  • Contraindication to spinal anesthesia.
  • BMI > 35 kg/m².
  • Impaired renal, hepatic and cardiac function.
  • Thyroid disease.
  • Body temperature >38 °C or < 36.5 °C.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Minya University Faculty of Medicine

    Minya

Other trials in Egypt

About this study

Official title: The Effect of Intravenous Granisetron Versus Intravenous Dexmedetomidine on Shivering Following Spinal Anesthesia in the Cesarean Section. a Randomized Controlled Comparative Trial .

The Aim of this study is to investigate and compare the efficacy of intravenous Dexmedetomidine (0.3 ug/kg) versus intravenous Granisetron (3 mg) in the prevention of shivering in parturient undergoing cesarean section under spinal anesthesia.

Read the detailed description

Study groups:

Randomization will be done according to computer guided table with sealed closed envelopes prepared by the supervisor, All study drugs will be prepared by the supervisor. Each group will be 25 patients.

Being tested
Dexmedetomidine, Granisetron, Placebo
Keywords
shivering after spinal anesthesia in cesarean section

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    label sticker

  • GranisetronDrug

    label sticker

  • PlaceboOther

    label sticker

Study groups in NCT06762860
Study groupRoleWhat they receive
Dexmedetomidine GroupActive comparatorPatients in this group will receive (0.3 ug/kg) intravenous dexmedetomidine added to normal saline to get 10 ml of colorless solution and injected over 10 minutes after clamping of the cord.
Receives: Drug: Dexmedetomidine
Granisetron GroupActive comparatorPatients in this group will receive 3mg intravenous Granisetron added to normal saline to get 10 ml of colorless solution and injected over 10 minutes immediately after clamping of the cord.
Receives: Drug: Granisetron
Control GroupPlacebo comparatorPatients in this group will receive 10 ml normal saline 0.9% over 10 minutes immediately after clamping of the cord (placebo control group).
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence and severity of post spinal shivering.

    -The Shivering will be graded on a scale Tsai and Chu [Tsai et al .,2001] : Grade 0= No shivering. Grade 1=Piloerection or peripheral vasoconstriction but no visible shivering. Grade 2=Muscular activity in only one muscle group. Grade 3=Muscular activity in more than one muscle group but not generalized. Grade 4=Shivering involving the whole body.

    Measured: every 10 minutes intraoperatively and every 15 minutes postoperatively for 4 hours

Secondary outcomes (3)
  1. change in the basal axillary temperature.

    Changes in basal axillary temperature (Celsius (°C) scale) of the patient after administration of tested drugs.

    Measured: preoperatively, immediately after spinal block and at 5 ,15 ,30 ,45 minutes and at the end of surgery, then every 15 minutes for 4 hour postoperatively

  2. change in the basal mean arterial blood pressure

    Changes in the basal non-invasive mean arterial blood pressure( millimetres mercury (mmHg)) of the patient after administration of tested drugs.

    Measured: preoperatively, immediately after spinal block and at 5 ,15 ,30 ,45 minutes and at the end of surgery, then every 15 minutes for 4 hour postoperatively.

  3. Change in the basal heart rate

    Change in the heart rate of the patient after administration of tested drugs (beat per minute)

    Measured: preoperatively, immediately after spinal block and at 5 ,15 ,30 ,45 minutes and at the end of surgery, then every 15 minutes for 4 hour postoperatively.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jan 2025
  2. Study start1 Jan 2024
  3. Primary completion30 Jan 2025 (estimated)
  4. Study completion28 Feb 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Group C: Patients in this group will receive 10 ml normal saline (0.9%) over 10minutes immediately after clamping of the cord (control group). Group D: Patients in this group will receive (0.3 ug/kg) intravenous Dexmedetomidine added to normal saline to get 10 ml of colorless solution and injected over 10 minutes after clamping of the cord. Group G: Patients in this group will receive 3 mg intravenous Granisetron added to normal saline to get 10 ml of colorless solution and injected over 10 minutes immediately after clamping of the cord.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
99 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06762860
Sponsor's protocol ID
postspinal shivering
Status last verified
Jan 2024
First submitted
3 Dec 2024
Last updated
9 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Dexmedetomidine and Granisetron in people with Postspinal Shivering, run by Minia University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence and severity of post spinal shivering. (time frame: every 10 minutes intraoperatively and every 15 minutes postoperatively for 4 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in